Establishment method of pH-sensitive mucoadhesive delivery system of rebaudioside A

By using a pH-sensitive mucoadhesion delivery system in acidic beverages, using zein and chitosan to form nanoparticles, the release problem of rebaudioside A in acidic beverages was solved, and the sweetness was extended and The reduction of bitter taste is suitable for use in acidic beverages.

CN119033058APending Publication Date: 2024-11-29JIANGSU UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411148929.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-21
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The application of rebaudioside A in food and beverages is limited by its subsequent bitterness and astringency, especially in acidic beverages, and the existing methods are expensive and have limited effects.

Method used

By establishing a pH-sensitive mucoadhesion delivery system, the use of zein and chitosan to form nanoparticles, control the release of rebaudioside A, ensuring stable release in an acidic environment, thereby reducing the release in a neutral environment, thereby Sweetener usage and bitterness.

Benefits of technology

It achieves stability in an acidic environment and release in a neutral environment, extends the release time of sweet taste, reduces the use of sweeteners, and significantly reduces the appearance of bitterness and astringent taste.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033058A_ABST
    Figure CN119033058A_ABST
Patent Text Reader

Abstract

The invention discloses an establishment method of a pH-sensitive mucoadhesive delivery system of rebaudioside A, and belongs to the technical field of sweeteners. According to the invention, a chitosan / zein-rebaudioside A nano delivery system loaded with rebaudioside A is prepared from zein and chitosan through an anti-solvent precipitation method. The nano delivery system obtained by the invention has pH sensitivity and mucosa adhesion, can be retained on the tongue mucosa, and allows more targeted and prolonged release of sweet taste near the taste bud. The use amount of a sweetening agent is reduced, so that the afterbitterness and astringent taste are reduced. The product can be used as a substitute of sugar in acidic beverages.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of sweeteners, and in particular relates to a method for establishing a pH-sensitive mucosal adhesion delivery system of rebaudioside A. Background Art

[0002] Some chronic diseases are increasing rapidly around the world, such as diabetes, hypertension and hyperlipidemia. The main cause of the disease is excessive intake of unhealthy foods such as high sugar, high fat and high salt. However, sweetness is indispensable to many foods. Under the stimulation of sweetness, the daily sugar intake often exceeds the maximum requirement of the human body. Therefore, various low-calorie sweeteners are popular among people. Natural sweeteners are more popular among sweeteners because of their healthier and more nutritious characteristics.

[0003] Stevia meets the growing demand for naturalness due to its safety and non-synthetic nature. Recent studies have shown that stevia products can also be used as health foods, showing benefits such as anti-hyperglycemia, hypolipidemic and anti-inflammatory. Stevia will be one of the most popular sugar substitutes for food in the near future. Rebaudioside A is one of the main components of steviol glycosides, and its use in food and beverages shows considerable heat (80°C) and pH (2-10) stability. It provides good sweetening ability, but it produces different degrees of aftertaste and astringency depending on the dosage, which limits its application. At present, various attempts have been made to reduce the aftertaste and astringency of rebaudioside A and increase its sweetness, such as hydrolysis, enzymatic and transglycosylation. However, these methods are expensive and the improvements obtained are limited.

[0004] Encapsulation has been used to mask unpleasant tastes and control release. The raw materials used are mostly proteins and polysaccharides, which can be added as food ingredients during production. Currently, encapsulation research is aimed at applications in solid foods, which require low solubility and release after exposure to liquid media, and are not suitable for acidic beverages. Summary of the invention

[0005] This study aims to solve the above problems with the bitter aftertaste and astringency of rebaudioside A. The purpose of the present invention is to provide a method for establishing a pH-sensitive mucoadhesive delivery system for rebaudioside A. The pH-sensitive mucoadhesive delivery system can be released under pH control and can be retained on the tongue mucosa, allowing for a more targeted and prolonged release of sweetness near the taste buds. By increasing the sweetness, the amount of sweetener required is reduced, and the bitterness is alleviated. It is expected to be applied to acidic beverages.

[0006] To achieve the above-mentioned purpose, a method for establishing a pH-sensitive mucoadhesive delivery system of rebaudioside A is carried out according to the following steps:

[0007] (1) Zein and rebaudioside A are dissolved in a 70% ethanol aqueous solution, and stirred evenly by magnetic force to obtain a zein-rebaudioside A mixed solution.

[0008] (2) Under magnetic stirring conditions, the zein-rebaudioside A mixture prepared in step (1) was added dropwise into deionized water at a volume ratio of 1:1.7. The ethanol was removed by rotary evaporation and the volume was fixed with distilled water. The pH of the solution was adjusted to 3.0 using 0.1 mol / L hydrochloric acid solution to obtain a zein-rebaudioside A nanoparticle dispersion.

[0009] (3) Under magnetic stirring conditions, the zein-rebaudioside A nanoparticle dispersion prepared in step (2) is added dropwise into an equal volume of a water-soluble chitosan solution to form a chitosan / zein-rebaudioside A nanoparticle dispersion.

[0010] Furthermore, in the steps (1), (2) and (3), the rotation speed of the magnetic stirring is 600 rpm and the time is 30 min.

[0011] Furthermore, in the step (1), the concentration of zein in the zein-rebaudioside A mixed solution is 20 mg / mL, and the concentration of rebaudioside A is 0.5 mg / mL.

[0012] Furthermore, the conditions for rotary evaporation in step (2) are 45° C., 80 mbar, and 60 min.

[0013] Furthermore, after the volume is fixed with distilled water in step (2), the concentration of rebaudioside A in the solution is 10 mg / mL.

[0014] Furthermore, the pH of the water-soluble chitosan solution in step (3) is 3.

[0015] Furthermore, the concentration of the water-soluble chitosan in step (3) is 1 to 10 mg / mL.

[0016] Beneficial effects of the present invention:

[0017] (1) The chitosan / zein-rebaudioside A nano-delivery system prepared by the present invention is pH-sensitive, maintains stability in an acidic environment, and releases in a neutral (oral) environment.

[0018] (2) The chitosan / zein-rebaudioside A nano-delivery system prepared by the present invention has mucosal adhesion and can be retained on the tongue mucosa, allowing for more targeted and prolonged release of sweetness near the taste buds, thereby reducing the amount of sweetener used, thereby reducing the aftertaste and astringency. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 is the particle size distribution diagram of the nanocomposite;

[0020] Figure 2 is the SEM image of the nanocomposite;

[0021] Figure 3 is the encapsulation efficiency graph of rebaudioside A in the nanocomplex;

[0022] Figure 4 This is the release rate graph of rebaudioside A from the nanocomplex at pH 6.8. DETAILED DESCRIPTION

[0023] The present invention is further described in detail below in conjunction with specific embodiments, which are intended to explain the present invention rather than to limit it.

[0024] The method for establishing a pH-sensitive mucosal adhesion delivery system of rebaudioside A described in the present invention comprises the following steps:

[0025] (1) Particle size distribution of nanoparticles: The particle size distribution of nanoparticles was measured by a laser particle size analyzer.

[0026] (2) Scanning electron microscopy: The freeze-dried sample was evenly spread on a conductive table with conductive glue, gold-sprayed, and observed at a voltage of 10 kV.

[0027] (3) The encapsulation efficiency of rebaudioside A and the release rate at pH 6.8 were determined by high performance liquid chromatography:

[0028] The formula for calculating the encapsulation efficiency is:

[0029]

[0030] The formula for calculating the release amount is:

[0031]

[0032] (4) Determination of mucosal adhesion ability: Mucin (0.1%, w / v) was prepared in 0.02 M phosphate buffer solution (pH 6.8). The nanocomplex was added to the mucin solution and incubated in an oscillator at 37°C and 70 rpm for 10 min. The particle size, PDI and potential were measured by a laser particle size analyzer.

[0033] Embodiment 1:

[0034] (1) Weigh 2 g of zein and 0.05 g of rebaudioside A and dissolve them in 100 mL of 70% ethanol aqueous solution, and stir them with a magnetic stirrer at 600 rpm for 30 min to obtain a zein-rebaudioside A mixed solution.

[0035] (2) Under magnetic stirring at 600 rpm, the mixed solution of zein-rebaudioside A obtained in step (1) was added dropwise into 170 mL of deionized water. Ethanol was removed by rotary evaporation at a temperature of 45° C. and a pressure of 80 mbar for 60 min, and the volume was fixed to 200 mL with distilled water. The pH of the solution was adjusted to 3.0 using 0.1 mol / L hydrochloric acid solution to obtain a zein-rebaudioside A nanoparticle dispersion.

[0036] (3) Under the condition of 600 rpm magnetic stirring, 10 mL of the zein-rebaudioside A nanoparticle dispersion prepared in step (2) was added dropwise to an equal volume of deionized water with a pH of 3. A portion of the dispersion was taken for particle size measurement. The results were as follows: Figure 1 After freeze-drying part of the supernatant, the results were observed by scanning electron microscopy. Figure 2 A portion of the dispersion was taken and the encapsulation efficiency of rebaudioside A in the nanocomposite was determined by liquid chromatography. The results are shown in Figure 3 The pH was adjusted to 6.8 with 0.1 mol / L sodium hydroxide, and the release rate of rebaudioside A was measured. The results are shown in Figure 4 The particle size after reaction with mucin is shown in Table 1.

[0037] Embodiment 2:

[0038] (1) Weigh 2 g of zein and 0.05 g of rebaudioside A and dissolve them in 100 mL of 70% ethanol aqueous solution, and stir them with a magnetic stirrer at 600 rpm for 30 min to obtain a zein-rebaudioside A mixed solution.

[0039] (2) Under magnetic stirring at 600 rpm, the mixture of zein-rebaudioside A obtained in step (1) was added dropwise into 170 mL of deionized water. Ethanol was removed by rotary evaporation at a temperature of 45° C. and a pressure of 80 mbar for 60 min, and the volume was fixed to 200 mL with distilled water. The pH of the solution was adjusted to 3.0 using 0.1 mol / L hydrochloric acid solution to obtain a zein-rebaudioside A nanoparticle dispersion.

[0040] (3) Under the condition of 600 rpm magnetic stirring, 10 mL of the zein-rebaudioside A nanoparticle dispersion prepared in step (2) was added dropwise to an equal volume of a water-soluble chitosan solution having a pH of 3, wherein the concentration of the chitosan solution was 1 mg / mL, to form a chitosan / zein-rebaudioside A nanoparticle dispersion. A portion of the dispersion was taken for particle size determination, and the result was as follows: Figure 1 After freeze-drying part of the supernatant, the results were observed by scanning electron microscopy. Figure 2 A portion of the dispersion was taken and the encapsulation efficiency of rebaudioside A in the nanocomposite was determined by liquid chromatography. The results are shown in Figure 3The pH was adjusted to 6.8 with 0.1 mol / L sodium hydroxide, and the release rate of rebaudioside A was measured. The results are shown in Figure 4 The particle size after reaction with mucin is shown in Table 1.

[0041] Embodiment 3:

[0042] (1) Weigh 2 g of zein and 0.05 g of rebaudioside A and dissolve them in 100 mL of 70% ethanol aqueous solution, and stir them with a magnetic stirrer at 600 rpm for 30 min to obtain a zein-rebaudioside A mixed solution.

[0043] (2) Under magnetic stirring at 600 rpm, the mixture of zein-rebaudioside A obtained in step (1) was added dropwise into 170 mL of deionized water. Ethanol was removed by rotary evaporation at a temperature of 45° C. and a pressure of 80 mbar for 60 min, and the volume was fixed to 200 mL with distilled water. The pH of the solution was adjusted to 3.0 using 0.1 mol / L hydrochloric acid solution to obtain a zein-rebaudioside A nanoparticle dispersion.

[0044] (3) Under the condition of 600rpm magnetic stirring, 10mL of the zein-rebaudioside A nanoparticle dispersion prepared in step (2) was added dropwise to an equal volume of a water-soluble chitosan solution with a pH of 3, wherein the concentration of the chitosan solution was 2mg / mL, to form a chitosan / zein-rebaudioside A nanoparticle dispersion. A portion of the dispersion was taken for particle size determination, and the result was as follows: Figure 1 After freeze-drying part of the supernatant, the results were observed by scanning electron microscopy. Figure 2 A portion of the dispersion was taken and the encapsulation efficiency of rebaudioside A in the nanocomposite was determined by liquid chromatography. The results are shown in Figure 3 The pH was adjusted to 6.8 with 0.1 mol / L sodium hydroxide, and the release rate of rebaudioside A was measured. The results are shown in Figure 4 The particle size after reaction with mucin is shown in Table 1.

[0045] Embodiment 4:

[0046] (1) Weigh 2 g of zein and 0.05 g of rebaudioside A and dissolve them in 100 mL of 70% ethanol aqueous solution, and stir them with a magnetic stirrer at 600 rpm for 30 min to obtain a zein-rebaudioside A mixed solution.

[0047] (2) Under magnetic stirring at 600 rpm, the mixture of zein-rebaudioside A obtained in step (1) was added dropwise into 170 mL of deionized water. Ethanol was removed by rotary evaporation at a temperature of 45° C. and a pressure of 80 mbar for 60 min, and the volume was fixed to 200 mL with distilled water. The pH of the solution was adjusted to 3.0 using 0.1 mol / L hydrochloric acid solution to obtain a zein-rebaudioside A nanoparticle dispersion.

[0048] (3) Under the condition of 600 rpm magnetic stirring, 10 mL of the zein-rebaudioside A nanoparticle dispersion prepared in step (2) was added dropwise to an equal volume of a water-soluble chitosan solution with a pH of 3, wherein the concentration of the chitosan solution was 5 mg / mL, to form a chitosan / zein-rebaudioside A nanoparticle dispersion. A portion of the dispersion was taken for particle size determination, and the results were as follows: Figure 1 After freeze-drying part of the supernatant, the results were observed by scanning electron microscopy. Figure 2 A portion of the dispersion was taken and the encapsulation efficiency of rebaudioside A in the nanocomposite was determined by liquid chromatography. The results are shown in Figure 3 The pH was adjusted to 6.8 with 0.1 mol / L sodium hydroxide, and the release rate of rebaudioside A was measured. The results are shown in Figure 4 The particle size after reaction with mucin is shown in Table 1.

[0049] Embodiment 5:

[0050] (1) Weigh 2 g of zein and 0.05 g of rebaudioside A and dissolve them in 100 mL of 70% ethanol aqueous solution, and stir them with a magnetic stirrer at 600 rpm for 30 min to obtain a zein-rebaudioside A mixed solution.

[0051] (2) Under magnetic stirring at 600 rpm, the mixture of zein-rebaudioside A obtained in step (1) was added dropwise into 170 mL of deionized water. Ethanol was removed by rotary evaporation at a temperature of 45° C. and a pressure of 80 mbar for 60 min, and the volume was fixed to 200 mL with distilled water. The pH of the solution was adjusted to 3.0 using 0.1 mol / L hydrochloric acid solution to obtain a zein-rebaudioside A nanoparticle dispersion.

[0052] (3) Under the condition of 600rpm magnetic stirring, 10mL of the zein-rebaudioside A nanoparticle dispersion prepared in step (2) was added dropwise to an equal volume of a water-soluble chitosan solution with a pH of 3, wherein the concentration of the chitosan solution was 10mg / mL, to form a chitosan / zein-rebaudioside A nanoparticle dispersion. A portion of the dispersion was taken for particle size determination, and the result was as follows: Figure 1 After freeze-drying part of the supernatant, the results were observed by scanning electron microscopy. Figure 2A portion of the dispersion was taken and the encapsulation efficiency of rebaudioside A in the nanocomposite was determined by liquid chromatography. The results are shown in Figure 3 The pH was adjusted to 6.8 with 0.1 mol / L sodium hydroxide, and the release rate of rebaudioside A was measured. The results are shown in Figure 4 The particle size after reaction with mucin is shown in Table 1.

[0053] Table 1 Particle size, PDI and potential of samples after binding with mucin in the examples

[0054] Example Particle size nm PDI Potential mV Example 1 272.70 0.43 -26.83 Example 2 366.10 0.39 -26.27 Example 3 417.97 0.31 -19.52 Example 4 3658.00 0.36 -2.48 Example 5 4483.33 0.33 -2.08

[0055] Depend on Figure 1 It can be seen that the particle size of the nanocomposite gradually increases with the increase of chitosan content, but the particle size is still less than 200nm, which is consistent with the size of oral nanoparticles. Figure 2 It can be seen that chitosan forms a film around the nanocomposite, but the shape of the particles can still be clearly seen. Figure 3 It can be seen that the addition of chitosan effectively improved the encapsulation efficiency of rebaudioside A. Figure 4 It can be seen that at a pH of 6.8, the release rate of rebaudioside A in the nanocomplex is greater than 75%. As shown in Table 1, the mucosal adhesion ability of Examples 4 and 5 is significantly higher than that of Example 1. Therefore, the method for establishing a pH-sensitive mucosal adhesion delivery system of rebaudioside A of the present invention can achieve pH sensitivity and can be retained on the tongue mucosa, allowing for more targeted and prolonged release of sweetness near the taste buds. Reduce the amount of sweetener used, thereby reducing the aftertaste and astringency.

[0056] Although some embodiments of the present invention have been given herein, those skilled in the art should understand that the embodiments of the present invention may be modified without departing from the technical solution of the present invention. The above embodiments are merely exemplary and should not be used as a limitation on the scope of the present invention.

Claims

1. A method for establishing a pH-sensitive mucoadhesive delivery system of rebaudioside A, characterized in that Follow the steps below: (1) dissolving zein and rebaudioside A in a 70% ethanol aqueous solution, and stirring the mixture evenly with a magnetic stirrer to obtain a zein-rebaudioside A mixed solution; (2) under magnetic stirring conditions, the zein-rebaudioside A mixed solution prepared in step (1) was added dropwise into deionized water in a volume ratio of 1:1.7; ethanol was removed by rotary evaporation, and the volume was fixed with distilled water; the pH of the solution was adjusted to 3.0 using 0.1 mol / L hydrochloric acid solution to obtain a zein-rebaudioside A nanoparticle dispersion; (3) Under magnetic stirring conditions, the zein-rebaudioside A nanoparticle dispersion prepared in step (2) is added dropwise into an equal volume of a water-soluble chitosan solution to form a chitosan / zein-rebaudioside A nanoparticle dispersion.

2. The method for establishing a pH-sensitive mucoadhesive delivery system of rebaudioside A according to claim 1, characterized in that The rotation speed of the magnetic stirring in steps (1), (2) and (3) is 600 rpm and the time is 30 min.

3. The method for establishing a pH-sensitive mucoadhesive delivery system of rebaudioside A according to claim 1, characterized in that In the step (1), the concentration of zein in the zein-rebaudioside A mixed solution is 20 mg / mL, and the concentration of rebaudioside A is 0.5 mg / mL.

4. The method for establishing a pH-sensitive mucoadhesive delivery system of rebaudioside A according to claim 1, characterized in that The conditions for rotary evaporation in step (2) are 45° C., 80 mbar, and 60 min.

5. The method for establishing a pH-sensitive mucoadhesive delivery system of rebaudioside A according to claim 1, characterized in that After the volume is fixed with distilled water in step (2), the concentration of rebaudioside A in the solution is 10 mg / mL.

6. The method for establishing a pH-sensitive mucoadhesive delivery system of rebaudioside A according to claim 1, characterized in that The pH of the water-soluble chitosan solution in step (3) is 3.

7. The method for establishing a pH-sensitive mucoadhesive delivery system of rebaudioside A according to claim 1, characterized in that The concentration of the water-soluble chitosan in step (3) is 1-10 mg / mL.